Biocon and Mylan launch fulphila — biosimilar to pegfilgrastim, in Canada
The approval of fulphila was based on a comprehensive package of analytical, non-clinical and clinical data, which confirmed that…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from US FDA
The Inspection has been closed with a “VAI” (Voluntary Action Indicated) classification in the EIR, for the three observations…
India needs to get into vaccine production in a big way: Kiran Mazumdar-Shaw
Biocon has started checking the temperatures of all people entering its premises -- employees and visitors
India should step up…
Biocon, Mylan win patent litigation for Insulin Glargine device patent in the US
Brings Biocon closer to commercialising Semglee in the US in 2020
Biocon has won a US court ruling that invalidated a Sanofi…
US FDA accepts Mylan and Biocon’s proposed biosimilar bevacizumab for review
The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is December 27, 2020
Biocon and Mylan announced that the US…
Kiran Mazumdar-Shaw named EY Entrepreneur of the Year India 2019
The award honours those who have contributed significantly towards nation building with their entrepreneurial ingenuity and…
USFDA issues Form 483 with five observations to Biocon’s Bengaluru facility
Form 483 is issued to a firm's management at the conclusion of an inspection when investigator has observed any conditions that in…
Biocon sees revenue growth of 14 per cent to Rs 1,784 crores in Q3FY20
EBITDA at Rs 480 crores, up 18 per cent
Dr Kiran Mazumdar-Shaw honoured with Australia’s highest civilian honour
The award was given for her significant service to advancing Australia's bilateral relationship with India, particularly in…
True North to invest Rs 536.25 cr in Biocon Biologics for 2.44 per cent stake
Post the completion of this transaction, Biocon will hold 96.07 per cent stake in Biocon Biologics